Form 8-K · Current report
Becton Dickinson 8-K, filed Aug 6, 2026
- Filed
- CIK
- 0000010795
- Accession no.
- 0001628280-26-053790
Summary
Becton Dickinson reported third-quarter fiscal 2026 revenue of $4.98 billion, up 5.4% as reported and 4.4% on a currency-neutral basis, with GAAP diluted EPS of $1.64 and adjusted diluted EPS of $3.23, and raised the midpoint of its full-year adjusted diluted EPS guidance to $12.62–$12.72 while expecting revenue growth toward the high end of its range. CEO Tom Polen attributed the quarter to momentum in the company's key growth platforms following the February 2026 spin-off of its former Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation and is now reported as discontinued operations.
Key points
- Quarterly revenue rose 5.4% as reported to $4.98 billion, with U.S. revenue up 6.9% and international revenue up 3.2%.
- Segment revenue growth was 4.5% for Medical Essentials, 4.9% for Connected Care, 6.6% for BioPharma Systems and 6.4% for Interventional.
- Year-to-date cash from continuing operations rose 33.3% to $2.1 billion and free cash flow rose 44.6% to $1.7 billion.
- BD announced a collaboration with Brazil-based pharmaceutical company EMS to launch semaglutide using BD's Vystra Injection Pen platform, and launched the Elyra Thulium Fiber Laser System for kidney stone care.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On August 6, 2026, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its third fiscal quarter ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.